Open-label randomized multi-center phase 2 study: gemcitabine cisplatin plus avelumab or gemcitabine cisplatin as first-line treatment of patients with locally advanced or metastatic urothelial bladder carcinoma: GCisAve
Gross-Goupil, Marine, Domblides, Charlotte, Lefort, Felix, Ravaud, AlainVolume:
107
Journal:
Bulletin du Cancer
DOI:
10.1016/S0007-4551(20)30280-0
Date:
June, 2020
File:
PDF, 271 KB
2020